Pasar al contenido principal

DISTRIBUCION ESPACIAL Y DIMERIZACION DE ERK: IMPLICACIONES EN LA CARCINOGENESIS

RTI2018-096658-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ras dimers: The novice couple at the ras-erk pathway ball

  • Herrero, Ana
  • Crespo, Piero
© 2021 by the authors., Signals conveyed through the RAS-ERK pathway constitute a pivotal regulatory element in cancer-related cellular processes. Recently, RAS dimerization has been proposed as a key step in the relay of RAS signals, critically contributing to RAF activation. RAS clustering at plasma membrane microdomains and endomembranes facilitates RAS dimerization in response to stimulation, promoting RAF dimerization and subsequent activation. Remarkably, inhibiting RAS dimerization forestalls tumorigenesis in cellular and animal models. Thus, the pharmacological disruption of RAS dimers has emerged as an additional target for cancer researchers in the quest for a means to curtail aberrant RAS activity., P.C. lab is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE); a grant from Asociación Española Contra el Cancer (AECC; GCB141423113); and CIBERONC from the Instituto de Salud Carlos III (ISCIII). A.H. is a fellow of the Juan de la Cierva program from the Spanish Ministry of Science (Grant IJCI-2017-32242; MICIU/AEI/FSE, UE).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

  • Zaballos, Miguel A.
  • Acuña-Ruiz, Adrián
  • Morante, Marta
  • Riesco-Eizaguirre, Garcilaso
  • Crespo, Piero
  • Santisteban, Pilar
Background: RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking ERK dimerization provides a therapeutic benefit in several human carcinomas. Here we analyzed the effects of DEL-22379, a relatively specific ERK dimerization inhibitor, on the activation of the RAS-to-ERK signaling cascade and on tumor-related processes in vitro and in vivo. Methods: We used a panel of four human anaplastic thyroid carcinoma (ATC) cell lines harboring BRAF or RAS mutations to analyze ERK dynamics and tumor-specific characteristics. We also assessed the impact of DEL-22379 on the transcriptional landscape of ATC cell lines using RNA-sequencing and evaluated its therapeutic efficacy in an orthotopic mouse model of ATC. Results: DEL-22379 impaired upstream ERK activation in BRAF- but not RAS-mutant cells. Cell viability and metastasis-related processes were attenuated by DEL-22379 treatment, but mostly in BRAF-mutant cells, whereas in vivo tumor growth and dissemination were strongly reduced for BRAF-mutant cells and mildly reduced for RAS-mutant cells. Transcriptomics analyses indicated that DEL-22379 modulated the transcriptional landscape of BRAF- and RAS-mutant cells in opposite directions. Conclusions: Our findings establish that BRAF- and RAS-mutant thyroid cells respond differentially to DEL-22379, which cannot be explained by the previously described mechanism of action of the inhibitor. Nonetheless, DEL-22379 demonstrated significant anti-tumor effects against BRAF-mutant cells in vivo with an apparent lack of toxicity, making it an interesting candidate for the development of combinatorial treatments. Our data underscore the differences elicited by the specific driver mutation for thyroid cancer onset and progression, which should be considered for experimental and clinical approaches., This work was supported by a grant from the Asociación Española Contra el Cancer (AECC; GCB141423113), jointly awarded to PS, PC and GR-E, and by the following national grants: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and PID2019-105303RB-I00/AEI/10.13.039/501100011033 from MICIN (to PS); RTI2018-096658B-100/AEI from MICIU/FEDER, UE) (to PC); PI14/01980 from Instituto Salud Carlos III (ISCIII) (to GR-E). PS, PC, GR-E and MAZ are members of CIBERONC ISCIII. MAZ, is a postdoctoral researcher funded by grant AECC-GCB141423113; AA-R was funded by an FPI fellowship from MINECO (SAF2013-44709-R) and a postdoctoral fellowship AECC-GCB141423113.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Scaffold coupling: ERK activation by transphosphorylation across different scaffold protein species

  • Martín-Vega, Ana
  • García-Gómez, Rocío
  • Herrero, Ana
  • Fuente-Vivas, Dalia de la
  • Parvathaneni, Swetha
  • Caloto, Rubén
  • Morante, Marta
  • Kriegsheim, Alex von
  • Bustelo, Xosé R.
  • Sacks, David B.
  • Casar, Berta
  • Crespo, Piero
RAS-ERK (extracellular signal–regulated kinase) pathway signals are modulated by scaffold proteins that assemble the components of different kinase tiers into a sequential phosphorylation cascade. In the prevailing model scaffold proteins function as isolated entities, where the flux of phosphorylation events progresses downstream linearly, to achieve ERK phosphorylation. We show that different types of scaffold proteins, specifically KSR1 (kinase suppressor of Ras 1) and IQGAP1 (IQ motif-containing guanosine triphosphatase activating protein 1), can bind to each other, forming a complex whereby phosphorylation reactions occur across both species. MEK (mitogen-activated protein kinase kinase) bound to IQGAP1 can phosphorylate ERK docked at KSR1, a process that we have named “trans-phosphorylation.” We also reveal that ERK trans-phosphorylation participates in KSR1-regulated adipogenesis, and it also underlies the modest cytotoxicity exhibited by KSR-directed inhibitors. Overall, we identify interactions between scaffold proteins and trans-phosphorylation as an additional level of regulation in the ERK cascade, with broad implications in signaling and the design of scaffold protein–aimed therapeutics., P.C. laboratory is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE), a grant from Asociación Española Contra el Cancer (AECC; GCB141423113), and CIBERONC from the Instituto de Salud Carlos III (ISCIII). B.C. is funded by PID2020-112760RB-100 from MICIU, FERO 2021.03, a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)–MICIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). X.R.B. is funded by “la Caixa” Banking Foundation (HR20-00164), the Castilla-León autonomous government (CSI252P18, CSI145P20, and CLC-2017-01), the MSI (RTI2018-096481-B-100), and the Asociación Española Contra el Cancer (GC16173472GARC). D.B.S. is supported by NIH Intramural Research Program. A.v.K. is supported by the Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ERK2 stimulates MYC transcription by anchoring CDK9 to the MYC promoter in a kinase activity-independent manner

  • Agudo-Ibáñez, Lorena
  • Morante, Marta
  • García-Gutiérrez, Lucía
  • Quintanilla, Andrea
  • Rodríguez, Javier M.
  • Muñoz Terol, Alberto
  • León, Javier
  • Crespo, Piero
The transcription factor MYC regulates cell proliferation, transformation, and survival in response to growth factor signaling that is mediated in part by the kinase activity of ERK2. Because ERK2 can also bind to DNA to modify gene expression, we investigated whether it more directly regulates MYC transcription. We identified ERK2 binding sites in the MYC promoter and detected ERK2 at the promoter in various serum-stimulated cell types. Expression of nuclear-localized ERK2 constructs in serum-starved cells revealed that ERK2 in the nucleus—regardless of its kinase activity—increased MYC mRNA expression and MYC protein abundance. ERK2 bound to the promoter through its amino-terminal insert domain and to the cyclin-dependent kinase CDK9 (which activates RNA polymerase II) through its carboxyl-terminal conserved docking domain. Both interactions were essential for ERK2-induced MYC expression, and depleting ERK impaired CDK9 occupancy and RNA polymerase II progression at the MYC promoter. Artificially tethering CDK9 to the MYC promoter by fusing it to the ERK2 insert domain was sufficient to stimulate MYC expression in serum-starved cells. Our findings demonstrate a role for ERK2 at the MYC promoter acting as a kinase-independent anchor for the recruitment of CDK9 to promote MYC expression., The work was supported by grants RTI2018-096658B-100 to P.C., PID2020-115903GB-100 to J.L., and PID2019-104867RB-100 to A.M. from the Spanish Ministry of Science (MCIN/AEI/10.13039/501100011033/, Spanish Government and FEDER); a grant from Asociación Española Contra el Cancer (AECC; GCB141423113) to P.C.; and a grant from CIBERONC from (CB16/12/00273) from Instituto de Salud Carlos III-FEDER to P.C. and A.M.